Back
Protagonist Therapeutics 10K Form
Sell
41
PTGX
Protagonist Therapeutics
Last Price:
22.44
Seasonality Move:
22.79%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-06 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2020-05-07 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2020-03-10 | 10K | PTGX/Protagonist Therapeutics Annual |
| 2019-11-06 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2019-08-07 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2019-05-08 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
Receive PTGX News And Ratings
See the #1 stock for the next 7 days that we like better than PTGX
PTGX Financial Statistics
Sales & Book Value
| Annual Sales: | $26.58M |
|---|---|
| Cash Flow: | $-31.71M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $4.37 |
| Price / Book: | 5.31 |
Profitability
| EPS (TTM): | -2.60000 |
|---|---|
| Net Income (TTM): | $-127.39M |
| Gross Margin: | -- |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Protagonist Therapeutics Earnings Forecast
Key Protagonist Therapeutics Financial Ratios
- The Research & Development expenses have been 474.87% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of PTGX is -479.27% of Total Revenues.
- Per Share Earnings over the last 9 years have been positive in 4 years.
Protagonist Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Current Symbol: | PTGX |
| CUSIP: | 74366E |
| Website: | protagonist-inc.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
PTGX Technical Analysis vs Fundamental Analysis
Sell
41
Protagonist Therapeutics (PTGX)
is a Sell
Is Protagonist Therapeutics a Buy or a Sell?
-
Protagonist Therapeutics stock is rated a Sell
The current Protagonist Therapeutics [PTGX] share price is $22.34. The Score for PTGX is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.